Intravitreal Tumor Necrosis Factor-Alpha Inhibitors for Neovascular Age-Related Macular Degeneration Suboptimally Responsive to Antivascular Endothelial Growth Factor Agents: A Pilot Study from the Pan American Collaborative Retina Study Group

Intravitreal Tumor Necrosis Factor-Alpha Inhibitors for Neovascular Age-Related Macular Degeneration Suboptimally Responsive to Antivascular Endothelial Growth Factor Agents: A Pilot Study from the Pan American Collaborative Retina Study Group

Author Wu, Lihteh Google Scholar
Arevalo, J. Fernando Google Scholar
Hernandez-Bogantes, Erick Google Scholar
Regatieri, Caio V. Autor UNIFESP Google Scholar
Roca, Jose A. Google Scholar
Farah, Michel E. Autor UNIFESP Google Scholar
Institution Inst Cirugia Ocular
King Khalid Eye Specialist Hosp
Johns Hopkins Univ
Universidade Federal de São Paulo (UNIFESP)
Clin Ricardo Palma
Abstract Purpose: To compare the short-term visual and anatomic outcomes after intravitreal injections of 2 different tumor necrosis factor-a inhibitors to continued antivascular endothelial growth factor (VEGF) therapy in eyes with choroidal neovascularization (CNV) secondary to age-related macular degeneration that responded suboptimally to anti-VEGF agents.Methods: Retrospective comparative case series of 26 eyes. Eyes were injected intravitreally with 1 mg infliximab, 2 mg infliximab, 2 mg adalimumab, or 1.25 mg bevacizumab. the main outcomes measured were the best-corrected visual acuity (BCVA) and the central macular thickness (CMT) at 3 months of follow-up.Results: the mean log minimal angle of resolution BCVA changed from 1.04 +/- 0.23 at baseline to 1.06 +/- 0.51 at 3 months (P = 0.9455) in the 1-mg infliximab group; 0.94 +/- 0.48 at baseline to 0.85 +/- 0.43 in the 2-mg infliximab group (P = 0.2802); 1.58 +/- 0.50 at baseline to 1.38 +/- 0.43 in the adalimumab group (P = 0.1116); and 1.08 +/- 0.1 at baseline to 1.03 +/- 0.16 in the bevacizumab group (P = 0.9928). the mean CMT changed from 387 +/- 54 mm at baseline to 342 +/- 108 mm (P = 0.1053) in the 1-mg infliximab group; 301 +/- 42 mm at baseline to 284 +/- 73 mm (P = 0.4854) in the 2-mg infliximab group; remained unchanged at 348 +/- 106 mm (P = 0.308) in the adalimumab group; and 362 +/- 66 mm to 340-27 mm in the bevacizumab group (P = 0.4622). Adverse events included uveitis in 37.5% (6/16) of eyes injected with infliximab.Conclusion: Intravitreal infliximab and adalimumab do not appear to benefit eyes with CNV that responded suboptimally to anti-VEGF agents. Intravitreal injections of infliximab may elicit a severe intraocular inflammatory reaction.
Language English
Date 2013-04-01
Published in Journal of Ocular Pharmacology and Therapeutics. New Rochelle: Mary Ann Liebert Inc, v. 29, n. 3, p. 366-371, 2013.
ISSN 1080-7683 (Sherpa/Romeo, impact factor)
Publisher Mary Ann Liebert Inc
Extent 366-371
Origin http://dx.doi.org/10.1089/jop.2012.0203
Access rights Closed access
Type Article
Web of Science ID WOS:000316947100017
URI http://repositorio.unifesp.br/handle/11600/36175

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account